Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

25 Feb, 2021

Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
Photo by Hack Capital on Unsplash

– Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the successful closing of a $95m Series C financing.
– Proceeds from the financing will be used to advance Xilio’s lead therapeutic candidates, XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4 mAb), into clinical trials.
– Investigational new drug (IND) applications for XTX202 and XTX101 are expected to be filed with the U.S. Food and Drug Administration (FDA) in 2021.
– The financing was led by Rock Springs Capital and was joined by Bain Capital Life Sciences, Deerfield Management Company and RA Capital Management, among other new investors.

Biotechnology Health Care Health Diagnostics North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: